SCHEMBL5842481

SCHEMBL5842481

O=C(Nc1ccc(-c2ccccc2)cc1)C1CC(=O)N(CCc2ccccc2)C1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.69
ALDH1A1 P00352 6/20 0.64
HPGD P15428 1/20 0.64
LMNA P02545 3/20 0.61
NPC1 O15118 2/20 0.61
GLA P06280 1/20 0.61
MAPT P10636 1/20 0.61
RAB9A P51151 1/20 0.61
POLB P06746 3/20 0.60
KMT2A Q03164 3/20 0.60
MEN1 O00255 2/20 0.60
TP53 P04637 1/20 0.60
L3MBTL1 Q9Y468 3/20 0.59
HTT P42858 1/20 0.59
KDM4E B2RXH2 1/20 0.58
GFER P55789 1/20 0.58
CYP2D6 P10635 1/20 0.57
SMAD3 P84022 1/20 0.57
GAA P10253 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5842500 0.91 SMN1; SMN2 (0.70) SMN1; SMN2ALDH1A1HPGDLMNAMAPT
SCHEMBL5843962 0.91 SMN1; SMN2 (0.69) SMN1; SMN2ALDH1A1HPGDLMNANPC1
SCHEMBL5841720 0.88 SMN1; SMN2 (0.66) SMN1; SMN2ALDH1A1HPGDLMNANPC1
SCHEMBL5842312 0.87 ALDH1A1 (0.66) SMN1; SMN2ALDH1A1HPGDLMNANPC1
SCHEMBL9886518 0.83 SMN1; SMN2 (0.60) SMN1; SMN2ALDH1A1HPGDLMNANPC1
SCHEMBL5842682 0.83 SMN1; SMN2 (0.68) SMN1; SMN2ALDH1A1HPGDLMNANPC1
SCHEMBL5842122 0.82 SMN1; SMN2 (0.61) SMN1; SMN2ALDH1A1HPGDLMNANPC1
SCHEMBL27001827 0.81 RXFP3 (0.84) SMN1; SMN2POLBTP53
SCHEMBL5841303 0.81 SMN1; SMN2 (0.66) SMN1; SMN2ALDH1A1HPGDLMNANPC1
SCHEMBL6617040 0.81 SMN1; SMN2 (0.48) SMN1; SMN2ALDH1A1HPGDLMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067549-B2 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2006-06-27 US disclosed
US-20050192292-A1 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192292-A1 Pyrrolidone carboxamides NPY1R, NPY5R, NPY2R SMN1; SMN2 3678/4885ALDH1A1 3034/4885HPGD 2405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.